; (C) how the lack of national standards for CBD and other hemp derived cannabinoid products affects the market; and (D) what is currently known about the safety and risk-benefit profile of CBD and other hemp derived cannabinoids, including what safety and toxicity data are available to support this knowledge and any relevant information about safety with regard to specific populations, such as children and pregnant individuals (3) Medical marijuana and cannabidiol research expansion act report A report detailing— (A) the number and type of appropriately registered individuals and entities under the Act, including the number of applications for registration received, the number of applications for registration approved, the number of applications for registration denied; (B) the impact of any rescheduling on cannabis or cannabis-derived substances to Schedules III–V or full decontrol, on further drug research, including new use and new safety research; (C) the number and type of any new drugs developed and approved pursuant to section 201 of Public Law 117–215 , the Medical Marijuana and Cannabidiol Research Expansion Act; and (D) the number and type of commercial drug manufacturer registrants approved and denied pursuant to section 202 of Public Law 117–215 , the Medical Marijuana and Cannabidiol Research Expansion Act. (4) Federal food, drug, and cosmetic act part j implementation report A report detailing— (A) administrative actions taken to implement part J of the Federal Food, Drug, and Cosmetic Act, as added by section 301 of this Act, including and with specific reference to actions taken to implement non-designated State medical cannabis product provisions, such as new drug, dietary supplement, cosmetic, and food use provisions